Executive Summary The healthcare sector is becoming increasingly attractive, and despite the risk of an expensive failed venture, non-traditional players have and will likely continue to take their chances to enter the field While the market has been profitable…
Executive Summary The COVID-19 pandemic has called into question many elements of the US healthcare system across key stakeholders, resulting in changes across patients, providers, payers, researchers, and manufacturers The pandemic has required many healthcare providers and patients to…
Verily recently announced its first major acquisition, a software platform known as SignalPath. SignalPath’s flagship software, TrialPath, digitizes and modulates individual protocols in a clinical trial, from budgeting to tracking point-of-care communication. The acquisition would fold SignalPath into Baseline, Verily’s clinical…
Executive Summary While 7 additional rare disease drugs were included on the 2020 NRDL in China, this development comes amid a backdrop of rare disease policy development signaling a move towards multi-channel funding mechanism to support more widespread patient…
Executive Summary Recent updates in the National Drug Reimbursement List (NRDL) have increasingly focused on the expansion of oncology products and highlighted the improving market access environment for innovative oncology therapies in China This effort first came under the…
Executive Summary: A CMS regulation from the Trump Administration requiring hospitals to post lists containing the list price, negotiated private payer prices, and self-pay rates for up to 300 shoppable services took effect in January 2021 but is still…
Executive Summary The Chinese National Reimbursement Drug List (NRDL) is managed and negotiated by the National Healthcare Security Administration (NHSA) and drugs listed on the NRDL are reimbursed by the public insurance Since 2017, on average, a significant price…
Executive Summary The Medical Fund Bill would increase drug spending up to 4% of the total healthcare spending in Poland The reimbursement applications can be reviewed as quickly as 180 days, reducing the typical time-to-market of two – three years…
Executive Summary Branded novel combinations are increasingly entering the oncology market but bring a unique set of challenges to gain access and pricing success Dynamics beyond demonstrating synergistic efficacy should be taken into consideration to optimize combination price / access…
Written by Tom Rutkowski, Patrick Buck, Kate Watkins, and Cameron Lam